It seems that YAP in the context of the Hippo pathway has a major role in controlling the expression of PDL1 in lung cancer, providing a link to EGFR resistance and PDL1 and rendering it an attractive target to overcome EGFR-TKI resistance in lung adenocarcinoma [22]. The gene discussed is YAP1; the disease is lung carcinoma.